株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注入式ドラッグデリバリー装置市場:成長率、傾向、および予測(2019年 - 2024年)

Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 871451
出版日 ページ情報 英文 119 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
注入式ドラッグデリバリー装置市場:成長率、傾向、および予測(2019年 - 2024年) Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年11月01日 ページ情報: 英文 119 Pages
概要

当レポートでは注入式ドラッグデリバリー装置市場について調査しており、市場概況や成長要因・阻害要因、装置タイプ・治療用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報をまとめています。

目次

第1章 イントロダクション

  • 研究成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 慢性疾患の罹患率の増加
    • 自己注射の需要増加につながる利点と利便性
    • 注射器の需要増加につながる生物製剤市場の成長
  • 市場阻害要因
    • 針によるけがと感染
    • 代替投与方法の使用の拡大
  • ポーターファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 装置タイプ別
    • 従来のドラッグデリバリー装置
    • 自己投与型ドラッグデリバリー装置
  • 治療用途別
    • 循環器疾患
    • 糖尿病
    • 腫瘍学
    • 自己免疫疾患
    • B型肝炎
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Alkermes
    • Baxter International, Inc.
    • Becton, Dickinson and Company
    • Eli Lilly and Company
    • Gerresheimer AG
    • Novartis AG
    • Pfizer, Inc.
    • Schott AG
    • テルモ株式会社
    • Teva Pharmaceutical Industries Ltd

第7章 市場機会および今後の動向

目次
Product Code: 52626

Market Overview

The injectable drug delivery devices market will show rapid growth due to the increasing prevalence of chronic diseases, benefits and convenience leading to increased demand of self injectors and growth of biologics market leading to increased demand for injectors.

The increasing prevalence of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect the emerging countries the most, as population growth is found to be the most significant factor in developing areas.

A major number of drugs and therapies that address these chronic ailments are now found to be available. However, the use of syringes in the management of any chronic ailment is inevitable. Syringes can either be a part of sample collection during diagnosis or treatment regimen, like osteoarthritis. Consequently, the rise in the prevalence of chronic diseases is expected the drive the growth of the market studied.

Furthermore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market are some of the other factors propelling the growth of the market.

Scope of the Report

As per the scope of the report, the injectable devices are being used to administer drugs either intravenously, through intramuscular or subcutaneously and are considered as injectable drug delivery devices. The injectable method is the frequently used method for drugs that have poor oral bioavailability, targeted drug delivery system, and delivery of drugs at the site of action. Injectable drug delivery is used in conditions such as hormonal imbalance, cystic fibrosis, autoimmune diseases, pain, Wilson's disease, hemophilia, hepatitis C, and ribose-5-phosphate isomerase deficiency.

Key Market Trends

Self-injectable Drug Delivery Devices is Anticipated to be the Dominant During the Forecast Period

There have been boundless innovations and developments in self-injectable devices driving the growth of the market. The other major advantages associated with self-injectable injections are found to be convenient usage and low healthcare cost. These self-injectables were developed by taking account of patient feedback, to provide the most adaptable device which has a high precision of drug delivery and is easy to use.

In addition, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market studied during the forecast period.

North America Region Dominates the Market of Injectable Drug Delivery Devices Market

North America has been found dominating the injectable drug delivery devices due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectables. According to the National Cancer Institute, 2018, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore the chemotherapy drugs are being delivered to these cancer patients through injectable devices. Hence, increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

There are also some of the other factors that include; the large pool of patient population, increasing healthcare expenditure, rising focus of various companies, increasing healthcare awareness, an increase in government funding. Hence all these factors are found associated with the growth of the market.

Competitive Landscape

The companies present in the market are found focusing on product innovations, expansions, finding new markets or innovating their core competency to expand their individual market share. There are also innovations taking place in injectable drug delivery systems that are the trend for the global injectable drug delivery market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

TABLE OF CONTENTs

1. INTRODUCTION

  • 1.1. Study Deliverables
  • 1.2. Study Assumptions
  • 1.3. Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1. Market Overview
  • 4.2. Market Drivers
    • 4.2.1. Increasing Prevalence of Chronic Diseases
    • 4.2.2. Benefits and Convenience leading to Increased demand of Self Injectors
    • 4.2.3. Growth of Biologics Market leading to Increased demand for injectors
  • 4.3. Market Restraints
    • 4.3.1. Injuries & Infections Caused by Needles
    • 4.3.2. Growing Use of Alternative Delivery Methods
  • 4.4. Porter's Five Force Analysis
    • 4.4.1. Threat of New Entrants
    • 4.4.2. Bargaining Power of Buyers/Consumers
    • 4.4.3. Bargaining Power of Suppliers
    • 4.4.4. Threat of Substitute Products
    • 4.4.5. Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1. By Devices Type
    • 5.1.1. Conventional Drug Delivery Devices
    • 5.1.2. Self-Injectable Drug Delivery Devices
      • 5.1.2.1. Prefilled Syringes
      • 5.1.2.2. Injectable Pens
      • 5.1.2.3. Auto-Injectors
      • 5.1.2.4. Needle-free Injectors
      • 5.1.2.5. Others
  • 5.2. By Therapeutic Application
    • 5.2.1. Cardiovascular Disease
    • 5.2.2. Diabetes
    • 5.2.3. Oncology
    • 5.2.4. Autoimmune Disorders
    • 5.2.5. Hepatitis B
    • 5.2.6. Others
  • 5.3. Geography
    • 5.3.1. North America
      • 5.3.1.1. US
      • 5.3.1.2. Canada
      • 5.3.1.3. Mexico
    • 5.3.2. Europe
      • 5.3.2.1. Germany
      • 5.3.2.2. UK
      • 5.3.2.3. France
      • 5.3.2.4. Italy
      • 5.3.2.5. Spain
      • 5.3.2.6. Rest of Europe
    • 5.3.3. Asia Pacific
      • 5.3.3.1. China
      • 5.3.3.2. Japan
      • 5.3.3.3. India
      • 5.3.3.4. Australia
      • 5.3.3.5. South Korea
      • 5.3.3.6. Rest of Asia-Pacific
    • 5.3.4. Middle East and Africa
      • 5.3.4.1. GCC
      • 5.3.4.2. South Africa
      • 5.3.4.3. Rest of Middle East and Africa
    • 5.3.5. South America
      • 5.3.5.1. Brazil
      • 5.3.5.2. Argentina
      • 5.3.5.3. Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1. Company Profiles
    • 6.1.1. Alkermes
    • 6.1.2. Baxter International, Inc.
    • 6.1.3. Becton, Dickinson and Company
    • 6.1.4. Eli Lilly and Company
    • 6.1.5. Gerresheimer AG
    • 6.1.6. Novartis AG
    • 6.1.7. Pfizer, Inc.
    • 6.1.8. Schott AG
    • 6.1.9. Terumo Corporation
    • 6.1.10. Teva Pharmaceutical Industries Ltd

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top